Silexion Initial Data on Orthotopic Pancreatic Cancer Models

 

Subcutaneously Administered SIL204 Reduces Both Primary Tumors and Metastases in Clinically Relevant Orthotopic Models in Human Pancreatic Cancer Cells

https://www.globenewswire.com/news-release/2025/03/05/3037405/0/en/Silexion-Therapeutics-Reports-Groundbreaking-Positive-Initial-Data-from-Systemic-Administration-of-SIL204-in-Orthotopic-Pancreatic-Cancer-Models.html